Photodynamic therapy for malignant pleural mesothelioma: The future of treatment?

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Malignant pleural mesothelioma is a deadly incurable cancer, with a median survival of approximately 9 months. The best available chemotherapy, arguably the standard of care, only yields a 40% response rate and an 11-week extension in median survival. Surgery, the modality most likely to be associated with prolonged remission, remains investigational and must always be combined with other modalities in an effort to treat the microscopic disease that will remain even after the most aggressive operations. One such modality, photodynamic therapy, is a light-based cancer treatment that has features making it particularly well suited as a component of a surgery-based multimodal treatment plan. Utilizing intraoperative photodynamic therapy has enabled development of a less drastic surgical procedure that is also yielding some encouraging survival results. A unique aspect of photodynamic therapy is its stimulation of a tumor-directed immune response, a feature that offers promise for designing future treatments.

Original languageEnglish
Pages (from-to)49-63
Number of pages15
JournalExpert Review of Respiratory Medicine
Issue number1
StatePublished - Feb 2011
Externally publishedYes


  • autologous tumor vaccine
  • extrapleural pneumonectomy
  • immunotherapy
  • laser
  • malignant pleural Mesothelioma
  • photodynamic therapy
  • photosensitizer
  • radical pleurectomy


Dive into the research topics of 'Photodynamic therapy for malignant pleural mesothelioma: The future of treatment?'. Together they form a unique fingerprint.

Cite this